Literature DB >> 28806575

Lessons from CTLA-4 deficiency and checkpoint inhibition.

Bernice Lo1, Ussama M Abdel-Motal2.   

Abstract

CTLA-4 is a crucial negative regulator of immune responses. Absence of CTLA-4 in mice causes autoimmunity and lethal multiorgan lymphocytic infiltration and tissue destruction. Recently, heterozygous CTLA4 or biallelic LRBA mutations leading to functional CTLA-4 deficiency and autoimmunity have been discovered. LRBA was identified as a novel regulator of steady-state CTLA-4 protein levels in Tregs and activated T cells. CTLA-4 deficiency due to checkpoint blockade cancer immunotherapy has also been found to lead to autoimmune reactions. Studies investigating the variable efficacy and adverse autoimmune responses to checkpoint therapy elucidated a role of the microbiota in promoting antitumor and autoreactive immune responses that are regulated by CTLA-4.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28806575     DOI: 10.1016/j.coi.2017.07.014

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  24 in total

Review 1.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

Review 2.  The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.

Authors:  Frédéric Rieux-Laucat; Aude Magérus-Chatinet; Bénédicte Neven
Journal:  J Clin Immunol       Date:  2018-06-17       Impact factor: 8.317

Review 3.  Acute Kidney Injury Induced by Immune Checkpoint Inhibitors.

Authors:  Ruixue Tian; Jin Liang; Rongshan Li; Xiaoshuang Zhou
Journal:  Kidney Dis (Basel)       Date:  2022-04-04

Review 4.  Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.

Authors:  Huimei Yi; Ying Li; Yuan Tan; Shujun Fu; Faqing Tang; Xiyun Deng
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

5.  Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.

Authors:  Xuhua Duan; Manzhou Wang; Xinwei Han; Jianzhuang Ren; Guohao Huang; Shuguang Ju; Qinghui Zhang
Journal:  Cell Cycle       Date:  2020-12-07       Impact factor: 4.534

Review 6.  Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.

Authors:  M Jamee; S Hosseinzadeh; N Sharifinejad; M Zaki-Dizaji; M Matloubi; M Hasani; S Baris; M Alsabbagh; B Lo; G Azizi
Journal:  Clin Exp Immunol       Date:  2021-05-03       Impact factor: 5.732

Review 7.  Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease.

Authors:  Taku Kuwabara; Yukihide Matsui; Fumio Ishikawa; Motonari Kondo
Journal:  Int J Mol Sci       Date:  2018-03-12       Impact factor: 5.923

Review 8.  T Cell Calcium Signaling Regulation by the Co-Receptor CD5.

Authors:  Claudia M Tellez Freitas; Deborah K Johnson; K Scott Weber
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

Review 9.  The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders.

Authors:  Danielle E Arnold; Deepak Chellapandian; Jennifer W Leiding
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

Review 10.  Targeting the spectrum of immune checkpoints in prostate cancer.

Authors:  Laura A Sena; Samuel R Denmeade; Emmanuel S Antonarakis
Journal:  Expert Rev Clin Pharmacol       Date:  2021-07-15       Impact factor: 4.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.